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Abstract: BACKGROUND No methodology is available to distinguish truly reduced myocardial flow
reserve (MFR) in positron emission tomography myocardial perfusion imaging (PET MPI) from seem-
ingly impaired MFR due to inadequate adenosine response. The adenosine-induced splenic switch-off
(SSO) sign has been proposed as a potential marker for adequate adenosine response in cardiac mag-
netic resonance (CMR). We assessed the feasibility of detecting SSO in nitrogen-13 ammonia PET MPI
using SSO in CMR as the standard of reference. METHODS AND RESULTS Fifty patients underwent
simultaneous CMR and PET MPI on a hybrid PET/MR device with co-injection of a gadolinium-based
contrast agent and nitrogen-13 ammonia during rest and adenosine-induced stress. In CMR, SSO was
assessed visually (positive vs negative SSO) and quantitatively by calculating the ratio of the peak signal
intensity of the spleen during stress over rest (SIR). In PET MPI, the splenic signal activity ratio (SAR)
was calculated as the maximal standard uptake value of the spleen during stress over rest. The median
SIR was significantly lower in patients with positive versus negative SSO in CMR (0.57 [IQR 0.49 to 0.62]
vs 0.89 [IQR 0.76 to 0.98]; P < .001). Similarly, median SAR in PET MPI was significantly lower in
patients with positive versus negative SSO (0.40 [IQR 0.32 to 0.45] vs 0.80 [IQR 0.47 to 0.98]; P < .001).
CONCLUSION Similarly to CMR, SSO can be detected in nitrogen-13 ammonia PET MPI. This might
help distinguish adenosine non-responders from patients with truly impaired MFR due to microvascular
dysfunction or multivessel coronary artery disease.
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Background. No methodology is available to distinguish truly reduced myocardial flow
reserve (MFR) in positron emission tomography myocardial perfusion imaging (PET MPI)
from seemingly impaired MFR due to inadequate adenosine response. The adenosine-induced
splenic switch-off (SSO) sign has been proposed as a potential marker for adequate adenosine
response in cardiac magnetic resonance (CMR). We assessed the feasibility of detecting SSO in
nitrogen-13 ammonia PET MPI using SSO in CMR as the standard of reference.
Methods and Results. Fifty patients underwent simultaneous CMR and PET MPI on a
hybrid PET/MR device with co-injection of a gadolinium-based contrast agent and nitrogen-13
ammonia during rest and adenosine-induced stress. In CMR, SSO was assessed visually (pos-
itive vs negative SSO) and quantitatively by calculating the ratio of the peak signal intensity of
the spleen during stress over rest (SIR). In PET MPI, the splenic signal activity ratio (SAR) was
calculated as the maximal standard uptake value of the spleen during stress over rest. The
median SIR was significantly lower in patients with positive versus negative SSO in CMR (0.57
[IQR 0.49 to 0.62] vs 0.89 [IQR 0.76 to 0.98]; P < .001). Similarly, median SAR in PET MPI was
significantly lower in patients with positive versus negative SSO (0.40 [IQR 0.32 to 0.45] vs 0.80
[IQR 0.47 to 0.98]; P < .001).
Conclusion. Similarly to CMR, SSO can be detected in nitrogen-13 ammonia PET MPI.
This might help distinguish adenosine non-responders from patients with truly impaired MFR
due to microvascular dysfunction or multivessel coronary artery disease. (J Nucl Cardiol 2020)
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Abbreviations
CAD Coronary artery disease
CMR Cardiac magnetic resonance
MBF Myocardial blood flow
MFR Myocardial flow reserve
MPI Myocardial perfusion imaging
PET Positron emission tomography
PET/MR Positron emission tomography/mag-
netic resonance
SAR Splenic activity ratio
SIR Splenic intensity ratio
SSO Splenic switch-off
INTRODUCTION
Positron emission tomography myocardial perfu-
sion imaging (PET MPI) is a robust and excellent tool
for quantitative and semi-quantitative assessment of
myocardial blood flow.1 Besides physical exercise or
dobutamine stress, pharmacological vasodilators such as
adenosine, regadenoson or dipyridamole are commonly
used to induce coronary hyperaemia. However, adequate
patient response to the latter is crucial to detect ischemia
or reduced myocardial flow reserve (MFR), and con-
versely, an inadequate response might result in a false-
negative result, decreased extent of ischemia or seem-
ingly reduced MFR. Rates of up to 5% to 10% of false-
negative MPI examinations have been reported,2,3 and
up to one-third of these may be attributed to inadequate
stress.4 Haemodynamic parameters such as an increase
in heart rate or a drop in systolic blood pressure are
commonly used to assess the response to vasodilators,
however, whether this reflects true coronary response
remains doubtful.5,6 Recently, for patients undergoing
stress cardiac magnetic resonance (CMR), the splenic
switch-off (SSO) sign, which is the visually assessed
decrease in splenic enhancement during adenosine
stress, has been proposed to be a marker for haemody-
namic response. Its validity as a marker for adenosine
response is based on the assumption that while adeno-
sine receptor stimulation results in splanchnic
vasodilation, the splenic circulation is not affected by
this mechanism, potentially even showing an opposite
reaction in the form of vasoconstriction.7,8 The utility of
SSO for identifying inadequate adenosine response in
CMR was first described in the CE-MARC study cohort,
where significantly more false-negative than true neg-
ative exams failed to show the sign.9 A subsequent study
in a real-world population also showed an increased
prevalence of SSO in true positive as compared to false-
negative CMR exams, although not reaching statistical
significance.10
In the present study, we test the hypothesis that
similarly to CMR, SSO can be assessed in nitrogen-13
ammonia PET MPI. To this aim, we assessed patients
undergoing simultaneous CMR and PET MPI with
adenosine-induced stress on a hybrid PET/MR device
with co-injection of a gadolinium-based contrast agent
(GBCA) and nitrogen-13 ammonia using SSO in CMR
as the standard of reference.
METHODS
Study design and population
Data of this prospective single-centre study were
derived from ongoing PET/MR projects. We assessed
patients who underwent cardiac PET/MR for evaluation
of coronary artery disease (CAD) or myocarditis and
obtained written informed consent from all patients. The
study protocol was approved by the local ethics com-
mittee (KEK-ZH-Nr. 2014-0187 and BASEC-Nr. 2018-
00170). Patients younger than 18 years, and patients
with contraindications against CMR (e.g. non-CMR-
compatible implanted cardiac devices, claustrophobia),
GBCA (known allergy, severe renal impairment),
adenosine (e.g. asthma, atrioventricular block) or PET
(e.g. pregnancy or breastfeeding) were excluded. The
patients were instructed to abstain from caffeine intake
for at least 12 hours prior to the examination. This work
was supported by a grant from the Swiss National
Science Foundation (SNSF, Project No. 175640).
Hybrid PET/MR acquisition protocol
A hybrid PET/MR scanner incorporating a 3 Tesla
MR and a PET scanner with time-of-flight (TOF) (Signa
PET/MR, GE Healthcare, Waukesha, WI, USA) was
used for the simultaneous acquisition of PET and CMR
datasets. For the stress protocol, a weight-adapted
adenosine infusion (140 lgkg-1min-1) with a total
length of 6 minutes was used. Three minutes into
adenosine stress, a body mass index-adapted dose of
nitrogen-13 ammonia (i.e. 200 to 600 megabecquerels
[MBq], 5.41 to 16.22 millicurie [mCi]) and a weight-
adapted dose of a gadolinium-based contrast agent
(Gadovist, Bayer AG, Zurich, Switzerland;
0.1 mmolkg-1) were injected.
PET data were acquired in list mode and recon-
structed as a static, dynamic (7 min divided into 21
frames: 9 9 10, 6 9 15, 3 9 20, 2 9 30, and
1 9 120 seconds), and an ECG-gated dataset (10 min)
using TOF reconstruction with VUE Point FX (2
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iterations and 16 subsets) and a 5-mm Hanning filter.
Standard DIXON-based maps were used for attenuation
correction.11 The resting PET images were acquired at
least 15 min after the stress acquisition using an
identical imaging protocol, after the injection of approx-
imately double the stress dose of nitrogen-13 ammonia.
For CMR MPI, three short-axis slices of the left
ventricle (basal, midventricular and apical; 10-mm slice
thickness) were acquired per cardiac cycle during
breath-hold. T1-weighted fast gradient echo sequences
with short TR and TE (TR 3.3 ms TE 1.2 ms, flip angle
20) were used after a 90 non-selective saturation
preparation pulse with a saturation delay time of 100 ms
and a typical acquired voxel size of 2.9 9 2.9 mm2 and
a matrix size of 128x128 (frequency 9 phase). To
reduce the slice acquisition time, a parallel imaging
acceleration factor of 2 (Asset) was used. The resting
CMR images were acquired at least 15 minutes after the
stress acquisition using an identical imaging protocol
and the same weight-adapted dose of a gadolinium-
based contrast agent.
MR analysis
Qualitatively, positive SSO in CMR was defined as
a visually perceivable lower splenic enhancement on
stress compared to rest first-pass CMR images, as
previously reported.9 The visual analysis was performed
by two independent readers in a blinded fashion. In the
case of disagreement, consensus with a third indepen-
dent reader was sought. Greyscale values were
normalized and identical values were applied to stress
and rest images for better comparability.
For quantitative SSO analysis, regions of interest
(ROIs) were drawn in the spleen on stress and rest
images to generate time–intensity curves using com-
mercially available software (CMR 42 Version 5.9.4,
Circle Cardiovascular Imaging, Calgary, Alberta,
Canada). Corrected peak signal intensities of the spleen
were calculated for stress and rest by subtracting
baseline intensity (pre-contrast) from peak intensity
after first-pass perfusion. Finally, the splenic intensity
ratio (SIR) was calculated by dividing the baseline-
corrected peak splenic intensity during stress by the
baseline-corrected peak splenic intensity at rest (SIR =
(splenic intensityStress-splenic intensityBaseline)/(splenic
intensityRest-splenic intensityBaseline)), (Figure 1).
PET analysis
To quantitatively assess SSO in PET, the activity
values in the stress and rest datasets were converted into
standardized uptake values (SUV) using the administered
tracer dose, tracer half-life and time of administration and
recorded using commercially available software (PMOD
Software Package Version 3.805, PMOD Technologies
LLC, Zürich, Switzerland). Volumes of interest were
placed in the spleen (10-mm radius sphere) and liver (20-
mm radius sphere) to generate time–activity curves from
the dynamic PET datasets. The splenic activity ratio (SAR)
was calculated as the peak splenic activity during stress
over the peak splenic activity at rest (SAR = splenic
activityStress/splenic activityRest), (Figure 2). The spleen-
to-liver activity ratio during stress (SLRStress) was calcu-
lated by dividing the peak splenic activity during stress by
the peak liver activity during stress (SLRStress = splenic
Figure 1. CMR short-axis first-pass perfusion images in a patient undergoing adenosine stress
PET/MR with positive SSO (*) defined as visually perceivable lower splenic enhancement on first-
pass stress (A) compared to rest (B) perfusion and the corresponding splenic signal intensity curves,
showing an SIR of 0.37 (C).
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activityStress/liver activityStress). Similarly, the spleen-to-
liver activity ratio during rest (SLRRest) was calculated by
dividing the peak splenic activity during rest by the peak
liver activity during rest (SLRRest = splenic activityRest/
liver activityRest). The stress-to-rest spleen-to-liver activity
ratio (SLRStress/Rest) was calculated by dividing the
SLRStress by SLRRest (SLRStress/Rest = SLRStress/SLRRest).
Quantitative myocardial blood flow (MBF) was obtained
from stress and rest PET scans, and global MFR was
calculated as the ratio of stress over rest MBF using
commercially available software (CSI 2017.7 Cedars-
Sinai Medical Center, Los Angeles, CA, USA). An
MFR\ 1.7 was defined as impaired flow reserve.12
Statistical analysis
The continuous parameters were tested for normal
distribution using the Kolmogorov–Smirnov test and are
presented as mean ± SD for normally distributed vari-
ables and as median and interquartile range (IQR) for
non-normally distributed variables. To compare groups,
T Test was used for normal distributed parameters and
Mann–Whitney-U-Test for non-normally distributed
parameters. For categorical parameters, a Chi2-Test
was used. Correlations were analysed using Spearman’s
rho. Cut-off values for activity ratios predicting positive
SSO in CMR were calculated using receiver operating
characteristic (ROC) analysis. For statistical analysis,
IBM SPSS Statistics version 22 (IBM Corporation,
Armonk, NY, USA) was used.
RESULTS
All 50 patients successfully underwent adenosine
stress PET/CMR. Detailed patient baseline characteris-
tics are given in Table 1.
Positive SSO in CMR was found in 37 patients
(74%). SIR, as derived from CMR, was significantly
lower in patients with positive versus negative SSO
(0.57 [IQR 0.49 to 0.62] vs 0.89 [IQR 0.76 to 0.98];
P\ .001; Figure 3a). Similarly, SAR, as derived from
PET, was significantly lower in patients with positive
versus negative SSO (0.4 IQR [0.32 to 0.45] vs 0.8 IQR
[0.47 to 0.98]; P = .001; Figure 3b). ROC analysis
revealed an area under the curve of 0.87 for SAR to
detect positive SSO and a cut-off value of 0.46
(Figure 3c). Using this threshold, a sensitivity of 81%,
specificity of 85%, PPV of 94% and NPV of 61% were
calculated. SSO and SAR B 0.46 showed moderate
agreement (j = 0.58, P\ .001). SIR and SAR showed a
weak, but statistically significant correlation (r = 0.38,
P = .007; Figure 4).
SLRStress was significantly lower than SLRRest (0.75
[IQR 0.55 to 1.15] vs. 2.05 [IQR 1.7 to 2.36]; P\ .001).
SLRRest did not differ significantly between patients
with positive versus negative SSO (2.05 [± 0.49] vs.
2.12 [± 0.55]; P = .666; Figure 5a). SLRStress was sig-
nificantly lower in patients with positive versus negative
SSO (0.68 [IQR 0.51 to 0.91] vs. 1.5 [IQR 0.98 to 1.83];
P\ .001; Figure 5b). ROC analysis for SLRStress to
detect positive SSO showed an area under the curve of
0.83 and a cut-off value of 0.92 (Figure 5c). Using this
threshold, a sensitivity of 78%, specificity of 85%, PPV
of 94% and NPV of 58% were calculated. SSO and
Figure 2. Nitrogen-13 ammonia PET in a patient undergoing adenosine stress PET/MR. A
transaxial slice through the spleen is shown. There is lower tracer activity of the spleen (*) during
stress (A) as compared to rest (B). Similarly, a quantitative assessment by splenic time activity
curves, showing a SAR of 0.29 (positive SAR) (C).
Bakula et al Journal of Nuclear Cardiology
Splenic switch-off as a novel marker for adenosine
SLRStress\ 0.92 showed moderate agreement (j = 0.55,
P\ .001).
SLRStress/Rest was significantly lower in patients
with positive versus negative SSO (0.32 [IQR 0.25 to
0.44] vs. 0.74 [IQR 0.36 to 1.05]; P = .002; Figure 6a).
The ROC analysis for SLRStress/Rest to detect positive
SSO showed an area under the curve of 0.79 and a cut-
off value of 0.46 (Figure 6b). Using this threshold, a
sensitivity of 78%, specificity of 69%, PPV of 88% and
NPV of 53% were calculated. SSO and SLRStress/
Rest\ 0.46 showed moderate agreement (j = 0.43,
P\ .01).
Mean MFR was significantly higher in patients with
positive vs negative SSO in CMR (3.38 ± 0.86 vs
2.53 ± 0.84; t = 3.09, df = 48, P = .003). Similarly, in
patients with SAR B 0.46 (positive SAR), the mean
MFR was significantly higher than in patients with SAR
above this threshold (3.43 ± 0.82 vs 2.69 ± 0.95;
t = 2.87, df = 48, P = .006). In patients with
SLRStress\ 0.92, the mean MFR was significantly
higher than in patients with SLRStress above this
Table 1. Baseline characteristics, risk factors, medication, medical history and PET MPI results in
patients with positive and negative SSO




Median age (years), n (IQR) 47 (25-62) 47 (28–58) 34 (21–69) 0.851
Male gender n (%) 39 (78) 28 (75.7) 11 (84.6) 0.503
Weight (kg), n (± SD) 79.6 (10.9) 80.4 (10.8) 77.3 (11.3) 0.379
Height (cm), n (± SD) 175 (9) 175 (9) 178 (8) 0.247
BMI (kg/m2), n (± SD) 25.9 (3.2) 26.4 (3.0) 24.4 (3.2) 0.53
Risk factors
Diabetes mellitus, n (%) 1 (2) 1 (3) 0 (0) 0.549
Dyslipidaemia, n (%) 15 (30) 12 (32) 3 (23) 0.527
Hypertension, n (%) 13 (26) 11 (30) 2 (15) 0.31
Family history, n (%) 13 (26) 10 (27) 3 (23) 0.78
Smoking, n (%) 19 (38) 17 (46) 2 (15) 0.051
Medication
Aspirin, n (%) 13 (26) 9 (24) 4 (31) 0.649
Beta blocker, n (%) 10 (20) 8 (22) 2 (15) 0.629
ACE inhibitor, n (%) 14 (28) 10 (27) 4 (31) 0.796
Statin, n (%) 15 (30) 10 (27) 5 (39) 0.439
Patient history
CAD, n (%) 14 (28) 10 (27) 4 (31) 0.796
Myocardial infarction, n (%) 7 (14) 4 (11) 3 (23) 0.273
Stenting, n (%) 8 (16) 5 (14) 3 (23) 0.418






















2.32 (0.72) 2.37 (0.62) 2.17 (0.95) 0.373
Rest MBF (mlmin-1g-1) (IQR) 0.73 (0.6–0.86) 0.67 (0.58–0.83) 0.77 (0.71–0.88) 0.141
MFR, (± SD) 3.16 (0.93) 3.38 (0.86) 2.53 (0.84) 0.003
Bold values indicate P\0.05
SSO splenic switch-off, IQR interquartile range, SD standard deviation, BMI body mass index, ACE angiotensine converting
enzyme, CAD coronary artery disease, CABG coronary artery bypass graft, MBF myocardial blood flow, MFR myocardial flow
reserve
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threshold (3.52 ± 0.82 vs 2.58 ± 0.81; t = 3.94, df = 48,
P\ .001). In patients with SLRStress/Rest\ 0.46, the
mean MFR was significantly higher than in patients with
SLRStress/Rest above this threshold (3.41 ± 0.90 vs
2.69 ± 0.80; t = 2.77, df = 48, P = .008).
DISCUSSION
To the best of our knowledge, this is the first study
demonstrating the feasibility of detecting and quantify-
ing SSO in adenosine stress nitrogen-13 ammonia PET
MPI. We established a novel indicator for the presence
of SSO in nitrogen-13 ammonia PET: the SAR, which
was calculated by dividing the peak splenic activity
during stress over the peak splenic activity at rest similar
to the SIR in CMR. A SAR of 0.46 was found to be a
highly accurate threshold to differentiate positive from
negative SSO, as depicted in CMR. It should be noted
that the results relate to the prediction of the visual
interpretation of SSO and not directly to the vasodilator
efficacy. Nevertheless, the study provides evidence that
PET-derived quantitation of spleen activity in the form
of SAR provides similar information on the adequacy of
adenosine response as the MR-derived SSO.
We have applied a comparable and easy measurable
method for quantification of SAR using peak activity
measurements, as shown for SIR in CMR.9,10 These
quantification methods resulted in some overlap in
results as compared to visual SSO in CMR. This could
be due to the fact that both timing and intensity can
influence the interpretation of visual splenic switch-off,
as opposed to SIR and SAR, which are derived from
single data points. In further studies, using coronary
anatomy as the standard of reference, alternative meth-
ods of quantification, i.e. the integral of the splenic
activity over time, or kinetic parameters could be
investigated. In contrast to CMR, where the same dose
of a gadolinium-based contrast agent is injected for
stress and rest, different activities of the tracer are
usually administrated for stress and rest examinations in
nitrogen-13 ammonia PET. Therefore, it is crucial to
convert activity values of the datasets into SUV, in order
to enable splenic activity comparison. This can be done
using PET scanners undergoing routine quality control
including dose calibration and commercially available
software. The nitrogen-13 ammonia dose used for SUV
calculations in our study was corrected with residual
dose measurements in case if manual injections, or an
automatic dose drawing system was used, with no
residual dose measurements. The residual dose in the
patient line and intravenous cannula was not measured,
also an approximated time of 1 minute between the dose
measurement and injection was used. Since this
approach was used in both, the stress and rest acquisi-
tions, there was no systemic bias influencing the ratio of
Figure 3. Median splenic SIR in CMR (A), median splenic SAR in PET (B) in patients with
positive versus negative SSO and ROC analysis for splenic SAR to detect positive SSO in CMR
(area under the curve of 0.87) (C).
Figure 4. Correlation of SIR and SAR.
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splenic activities. Also the doses individually were
within the linear sensitivity spectrum of the scanner,
therefore we can assume that this approach works
correctly. Alternatively, organs like the liver can be used
as a reference allowing the calculation of dose-indepen-
dent ratios. Therefore, we additionally showed that the
median spleen-to-liver activity ratio under stress was
significantly lower in patients with visual SSO in CMR
compared to patients without visual SSO.
Only two patients in our study had impaired MFR,
which did not allow for statistical analysis of the
differences in SAR, or SLR between patients with
normal and impaired MFR in this population. In the two
patients with impaired MFR, the threshold for SAR
correctly differentiated a true positive from false pos-
itive: Invasive coronary angiography of one patient with
an MFR of 1.11 and a SAR of 0.41 (i.e. positive SAR)
revealed obstructive multivessel CAD. By contrast, in
the second patient (21-year old, with no cardiovascular
risk factors except light smoking) with impaired MFR of
1.64 but a SAR of 0.93 (i.e. negative SAR), coronary
computed tomography showed normal coronary arteries,
suggesting inadequate adenosine response as the reason
for the false-positive PET finding (Figure 7). As SAR is
Figure 6. Median stress-to-rest spleen-to-liver activity ratio in PET in patients with positive versus
negative SSO (A) and ROC analysis for stress-to-rest spleen-to-liver activity ratio to detect positive
SSO in CMR (area under the curve of 0.79) (B).
Figure 5. Median spleen-to-liver activity ratio at rest in PET (A), median spleen-to-liver activity
ratio under stress in PET (B) in patients with positive versus negative SSO and ROC analysis for
spleen-to-liver activity ratio under stress to detect positive SSO in CMR (area under the curve of
0.83) (C).
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a novel parameter, it has not yet been used in MPI PET.
However, the clinical advantage of SAR might warrant
its implementation, especially in patients with reduced
MFR in whom an adenosine non-responder or inade-
quate response cannot be excluded. Taking into account
that a considerable number of patients might be under-
stressed,2–4 a novel marker in nitrogen-13 ammonia MPI
PET would be more than welcome to differentiate truly
from seemingly reduced MFR. This can help to further
improve the already established substantial diagnostic
and prognostic value of MFR in nitrogen-13 ammonia
MPI PET.13
In our cohort, mean MFR in PET was significantly
higher in patients with a splenic SAR B 0.46 (i.e.
positive SAR) as compared to patients with a SAR[
0.46 (i.e. negative SAR). This was also true for the
other activity ratios in PET MPI: SLRStress and SLRStress/
Rest. The conclusion that this observation might be due to
a more pronounced coronary adenosine response has to
be drawn with caution as MFR can be reduced in
patients with an adequate adenosine response due to
severe CAD or microvascular dysfunction. Also,
although SAR showed the best agreement with visual
SSO in CMR, patients with SLRStress\ 0.92 and
SLRStress C 0.92 showed the most significant differ-
ences in MFR, suggesting the best correlation with the
haemodynamic response to vasodilator stress. All three
activity ratios should be compared, when validating SSO
in PET MPI against coronary anatomy.
There is growing evidence about the incremental
value of SSO in stress CMR to predict adequate
adenosine response,9,10,14,15 although there is also liter-
ature demonstrating that SSO in CMR failed to predict
false-negative adenosine results after caffeine intake.16
Only one study examined this phenomenon in Rb-82
PET MPI, 17 despite the fact that initial observations
about reduced splenic tracer activity during stress have
been described in 1984.18 In line with the former CMR
studies, Bami et al found an incremental prognostic
value of a splenic response ratio in PET.17 However, this
PET study did not aim at cross-validation versus a
standard of reference, while the simultaneity of assess-
ment of both markers through co-injection and use of a
hybrid PET/MR device virtually excluded intrapatient
variability of adenosine response in our study. Prognos-
tic outcomes were not the subject of our study, as the
population was not representative of a typical population
of patients undergoing PET MPI.
Compared to CMR studies by Manisty et al (90%) 9
and Hoskins et al (89%), 10 positive SSO in our study
was less frequent. Reasons for the slightly lower
prevalence (74%) in our cohort might be the different
doses of adenosine used in the studies. While we used a
fixed adenosine infusion dose of 140 lgkg-1min-1,
both other studies titrated adenosine up to
175 lgkg-1min-1. Indeed, current guidelines for
nuclear cardiology procedures recommend a fixed infu-
sion of 140 lgkg-1min-1 adenosine,19 supported by
Fig. 7. An example of two patients with impaired MFR. Invasive coronary angiography of patient
#1 (top) with impaired MFR of 1.11 and a SAR of 0.41 (positive SSO: *) revealed severe CAD with
a subtotal stenosis of the ostial left circumflex artery (A), occluded RCA (B) and subtotal stenosis
of LIMA-LAD bypass graft, indicating truly reduced MFR. Coronary computed tomography (C,D)
in patient #2 (bottom) with impaired MFR of 1.64 and a SAR of 0.93 (negative SSO: **) excluded
obstructive CAD or calcifications, indicating failed adenosine response as the cause for the
impaired MFR.
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the fact that uptitrating adenosine beyond this point does
not result in further hyperaemia,20 even though an
increase in the rate of SSO can be observed.21 In
accordance with this, only two patients in our study
showed a reduced MFR, while one of those should be
considered a true non-responder.
NEW KNOWLEDGE GAINED
SSO in PET MPI, as derived from SAR, corre-
sponds with SSO in CMR and can be used as a marker
for adequate adenosine response.
LIMITATIONS
The low patient number may be perceived as a
limitation of our study. However, as a pilot study used
for the initial validation of SAR in selected patients
undergoing hybrid PET/MR MPI, we believe that it
allows drawing the above conclusions. Furthermore, we
did not assess the predictive value of SAR to identify
non-responders as only two patients had an impaired
MFR. The patient population, consisting of both patients
with coronary artery disease, as well as myocarditis may
not be representative of patients undergoing routine PET
MPI, so the applicability of the results should be verified
in further studies, also including patients not abstaining
from caffeine. It should be also noted that while the
results of our study may be applicable to patients
undergoing dipyridamole stress, the splenic switch-off
sign is not observed after administration of regadenoson
due to its selective receptor affinity or during dobu-
tamine stress.7,9 Furthermore, since this study
demonstrated the feasibility of detecting SSO in PET
MPI as defined by visual SSO in CMR, further assess-
ment of this sign using invasive coronary angiography
and coronary computed angiography as an anatomical
correlate is needed. Finally, our binary system of
categorizing patients as responders and non-responders
might be an over-simplification as a more graded
adenosine response is suggested by some studies,
depending on receptor density and responsiveness of
adenosine receptors, as well as the distribution of SIR
and activity ratios in our study suggest a graded response
of splenic perfusion to adenosine stress.
CONCLUSION
Similarly to CMR, SSO can be detected in nitrogen-
13 ammonia PET MPI. This might help distinguish
adenosine non-responders from patients with truly
impaired MFR due to microvascular dysfunction or
multivessel CAD.
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